About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
PMID: 35763871 Journal: EUROPEAN JOURNAL OF CANCER Year: 2022 Reference: Eur J Cancer. 2022 Jun 25;172:119-129. doi: 10.1016/j.ejca.2022.05.033. Impact factor: 9.162 Publication type: Paper in international publication Authors: Fajardo, Raquel D; Scarzello, Giovanni; Minard-Colin, Veronique; Ben-Arush, Myriam; Terwisscha Van Scheltinga, Sheila; Bernier, Valerie; Gallego, Soledad; Bisogno, Gianni; Merks, Johannes H M; Cesen, Maja et al. DOI: 10.1016/j.ejca.2022.05.033
PMID: 35767111 Journal: JOURNAL OF CLINICAL IMMUNOLOGY Year: 2022 Reference: J Clin Immunol. 2022 Jun 29. pii: 10.1007/s10875-022-01305-6. doi: 10.1007/s10875-022-01305-6. Impact factor: 8.317 Publication type: Paper in international publication Authors: Schneiderman, Jennifer; Caorsi, Roberta; Lucioni, Federica; Volpi, Stefano; Giardino, Stefano; Lang, Abigail; Khojah, Amer; Papadatou, Ionanna; Faraci, Maura; Gattorno, Marco et al. DOI: 10.1007/s10875-022-01305-6
PMID: 35804055 Journal: BONE MARROW TRANSPLANTATION Year: 2022 Reference: Bone Marrow Transplant. 2022 Jul 8. pii: 10.1038/s41409-022-01750-2. doi: 10.1038/s41409-022-01750-2. Impact factor: 5.483 Publication type: Paper in international publication Authors: Martino, Rodrigo, Fernandez-Sojo, Jesus, Horton, Roger, Cid, Joan, Azqueta, Carmen, Garcia-Buendia, Ana, Valdivia, Elena, Martorell, Lluis, Rubio-Lopez, Nuria, Codinach, Margarita et al. DOI: 10.1038/s41409-022-01750-2
PMID: 35715627 Journal: Targeted Oncology Year: 2022 Reference: Target Oncol. 2022 Jun 17. pii: 10.1007/s11523-022-00888-9. doi: 10.1007/s11523-022-00888-9. Impact factor: 4.493 Publication type: Paper in international publication Authors: Trippett, Tanya, Toledano, Helen, Campbell Hewson, Quentin, Verschuur, Arnauld, Langevin, Anne-Marie, Aerts, Isabelle, Howell, Lisa, Gallego, Soledad, Rossig, Claudia, Smith, Amy et al. DOI: 10.1007/s11523-022-00888-9
PMID: 33332189 Journal: JOURNAL OF CLINICAL ONCOLOGY Year: 2021 Reference: J Clin Oncol. 2021 Feb 1;39(4):295-307. doi: 10.1200/JCO.20.02529. Epub 2020 Dec 17. Impact factor: Publication type: Paper in international publication Authors: Aleinikova, Olga; Ansari, Marc; Ariffin, Hany; Bader, Peter; Balduzzi, Adriana; Bierings, Marc; Buechner, Jochen; Burkhardt, Birgit; Corbacioglu, Selim; Dalle, Jean-Hugues et al. DOI: 10.1200/JCO.20.02529
PMID: 33084101 Journal: EUROPEAN JOURNAL OF HAEMATOLOGY Year: 2021 Reference: Eur J Haematol. 2021 Feb;106(2):196-204. doi: 10.1111/ejh.13536. Epub 2020 Nov 17. Impact factor: Publication type: Paper in international publication Authors: Alonso, Laura; Balas, Antonio; Benito, Ana; Bueno, David; Couselo, Jose Miguel; de Heredia, Cristina Diaz; Diaz-Almiron, Mariana; Ferreras, Cristina; Fuster, Jose Luis; Gomez Lopez, Alicia et al. DOI: 10.1111/ejh.13536
PMID: 32472454 Journal: Clinical & Translational Oncology Year: 2021 Reference: Clin Transl Oncol. 2021 Jan;23(1):183-189. doi: 10.1007/s12094-020-02399-3. Epub 2020 May 29. Impact factor: Publication type: Paper in international publication Authors: Bautista, F; Canete, A; Castaneda, A; de Rojas, T; Guerra-Garcia, P; Hladun, R; Juan-Ribelles, A; Molero, M; Moreno, L; Perez-Martinez, A et al. DOI: 10.1007/s12094-020-02399-3
PMID: 33462728 Journal: JOURNAL OF CLINICAL IMMUNOLOGY Year: 2021 Reference: J Clin Immunol. 2021 May;41(4):748-755. doi: 10.1007/s10875-020-00961-w. Epub 2021 Jan 18. Impact factor: Publication type: Paper in international publication Authors: Alonso, Laura; Bueno, David; de Paz, Raquel; Diaz de Heredia, Cristina; Gimeno, Ramon; Lopez-Granados, Eduardo; Mendez-Echevarria, Ana; Mozo, Yasmina; Perez-Martinez, Antonio; Querol, Sergi et al. DOI: 10.1007/s10875-020-00961-w
PMID: 32278616 Journal: NEFROLOGIA Year: 2020 Reference: Nefrologia (Engl Ed). 2020 May-Jun;40(3):265-271. doi: 10.1016/j.nefro.2020.03.002. Epub 2020 Apr 3. Impact factor: Publication type: Clinical guide Authors: Alonso, Angel; Alonso-Titos, Juana; Beneyto, Isabel; Cabello, Mercedes; Crespo, Marta; Diaz-Corte, Carmen; Franco, Antonio; Gonzalez-Roncero, Francisco; Guirado, Luis; Gutierrez, Elena et al. DOI: 10.1016/j.nefro.2020.03.002
PMID: 32837964 Journal: Anales de pediatria Year: 2020 Reference: An Pediatr (Engl Ed). 2020 Aug;93(2):132-133. doi: 10.1016/j.anpede.2020.05.002. Epub 2020 Jul 1. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Diaz de Heredia, Cristina; Moreno, Lucas; Riviere, Jacques G; Soler Palacin, Pere; Velasco Puyo, Pablo et al. DOI: 10.1016/j.anpede.2020.05.002
PMID: 33614543 Journal: Frontiers in Pediatrics Year: 2020 Reference: Front Pediatr. 2021 Feb 5;8:614521. doi: 10.3389/fped.2020.614521. eCollection 2020. Impact factor: 2.634 Publication type: Paper in international publication Authors: Esperanza-Cebollada, Elena, Vega-Garcia, Nerea, Perez-Jaume, Sara, Guerra-Garcia, Pilar, Perez-Martinez, Antonio, Garcia-Abos, Miriam, Robles Ortiz, Reyes, Pisa, Sandra, Adan, Rosa, Diaz de Heredia, Cristina et al. DOI: 10.3389/fped.2020.614521
PMID: 33564657 Journal: Biomedicine hub Year: 2020 Reference: Biomed Hub. 2020 Jul 17;5(2):1-11. doi: 10.1159/000509272. eCollection 2020 May-Aug. Impact factor: 0 Publication type: Editorail in international publication Authors: Manu Pereira, Maria Del Mar, Gutierrez Valle, Victoria, Gutierrez Ibarluzea, Inaki, Kent, Alastair, Cattaneo, Ivana, Jagielska, Beata, Belina, Ivica, Tumiene, Birute, Ward, Adrian, Papaluca, Marisa et al. DOI: 10.1159/000509272
The association, once again, has shown its commitment to oncological research with a donation of €19,197 to the Cancer and Hematological Diseases Group for Children at VHIR.
The prestigious journal The Lancet has published the results of this study, which is the result of more than 20 years of pre-clinical research and 7 years of patient follow-up.
During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.
